Cisen Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	649.16	1,161	983.39	997.95	938.98	661.42
Short-Term Investments	490.38	357.58	154.11	236.27	-	-
Trading Asset Securities	2,205	1,275	1,638	1,550	1,485	1,875
Cash & Short-Term Investments	3,345	2,794	2,775	2,784	2,424	2,537
Cash Growth	31.05%	0.66%	-0.32%	14.87%	-4.46%	7.36%
Accounts Receivable	898.24	1,257	1,363	1,272	1,048	738.84
Other Receivables	9.23	3.99	4.24	9.25	11.35	8.77
Receivables	907.47	1,261	1,367	1,281	1,060	747.61
Inventory	724.45	810.43	708.22	580.43	594.65	572.12
Other Current Assets	211.38	97.1	119.41	99.63	66.45	93.84
Total Current Assets	5,188	4,962	4,970	4,745	4,145	3,950
Property, Plant & Equipment	1,699	1,546	1,390	1,489	1,591	1,637
Long-Term Investments	5.51	665.48	602.27	265.08	308.01	246.59
Other Intangible Assets	198	203.97	211.6	213.03	210.82	207.92
Long-Term Deferred Tax Assets	70.83	77.41	79.83	86.72	81.65	63.12
Long-Term Deferred Charges	0.69	0.47	1.91	3.86	2.05	-
Other Long-Term Assets	459.01	98.74	81.94	12.87	25.54	61.09
Total Assets	7,621	7,554	7,338	6,815	6,364	6,166
Accounts Payable	711.15	549.49	468.01	459.71	434.97	502.13
Accrued Expenses	81.45	114.89	139.77	259.48	214.52	219.74
Short-Term Debt	11.94	71.98	34.8	57.79	130	330
Current Portion of Long-Term Debt	7.41	32.63	-	-	-	-
Current Portion of Leases	-	2.64	3.34	0.3	2.72	-
Current Income Taxes Payable	34.8	11.71	34.67	5.61	1.18	8.24
Current Unearned Revenue	59.08	78.11	100.16	118.78	70.05	70.53
Other Current Liabilities	376.42	627.39	589.17	380.24	365.5	153.7
Total Current Liabilities	1,282	1,489	1,370	1,282	1,219	1,284
Long-Term Debt	21.37	7.7	128.5	100	-	-
Long-Term Leases	2.34	0.89	4.03	0.51	10.91	-
Long-Term Unearned Revenue	105.03	57.17	56.25	65.36	74.43	75.02
Long-Term Deferred Tax Liabilities	15.78	12.28	12.68	11.46	3.87	4.4
Total Liabilities	1,427	1,567	1,571	1,459	1,308	1,364
Common Stock	452.75	452.75	452.78	453.31	453.33	453.35
Additional Paid-In Capital	1,935	1,929	1,919	1,913	1,863	1,844
Retained Earnings	3,767	3,570	3,358	2,989	2,774	2,556
Treasury Stock	-	-	-0.08	-19.77	-32.74	-50.49
Comprehensive Income & Other	-2.26	-2.71	-2.69	-2.93	-3.07	-2.12
Total Common Equity	6,153	5,950	5,727	5,332	5,055	4,801
Minority Interest	41.28	37.39	39.1	23.64	0.75	1
Shareholders' Equity	6,194	5,987	5,766	5,356	5,056	4,802
Total Liabilities & Equity	7,621	7,554	7,338	6,815	6,364	6,166
Total Debt	43.06	115.83	170.67	158.61	143.63	330
Net Cash (Debt)	3,302	2,678	2,604	2,625	2,280	2,207
Net Cash Growth	33.54%	2.81%	-0.79%	15.15%	3.32%	-2.48%
Net Cash Per Share	7.24	5.89	5.75	5.78	5.05	4.88
Filing Date Shares Outstanding	452.75	452.75	452.76	451.36	449.83	447.8
Total Common Shares Outstanding	452.75	452.75	452.76	451.34	449.83	447.8
Working Capital	3,906	3,473	3,600	3,463	2,926	2,666
Book Value Per Share	13.59	13.14	12.65	11.81	11.24	10.72
Tangible Book Value	5,955	5,746	5,516	5,119	4,844	4,593
Tangible Book Value Per Share	13.15	12.69	12.18	11.34	10.77	10.26
Buildings	-	1,277	1,275	1,188	1,191	975.57
Machinery	-	2,109	2,092	1,903	1,797	1,494
Construction In Progress	-	405.8	66.68	207.17	199.71	582.04

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.